Katherine Hermida Alava

Katherine Hermida Alava

Auto-generated profile, based on publicly available information

Katherine Hermida Alava


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in Medical Mycology
Verified
Journal Article
Closed access
TDTomás Brito Devoto
Tomás Brito Devoto
KAKatherine Stefania Hermida Alava
Katherine Stefania Hermida Alava
SPSantiago J Pola
Santiago J Pola
RPRosana Pereda
Rosana Pereda
EREtelvina Rubeglio
Etelvina Rubeglio
MCMaria Cuestas
Maria Cuestas
In cystic fibrosis (CF) patients, fungal colonization of the respiratory tract is frequently found. Aspergillus fumigatus is the most frequently recorded and is associated with loss of pulmonary function and allergic disease (ABPA). The knowledge on prevalence rates of filamentous fungi in CF patients in Latin America is scarce. One hundred and seventy-six fungal isolates recovered from the upper respiratory tract of CF patients from Argentina were identified to species by morphology and DNA sequencing. In total, 90% of CF patients were colonized by Aspergillus sp., followed by Exophiala sp. (14%) and Scedosporium sp. (10%). Among Aspergillus, six species complexes (Fumigati, Flavi, Terrei, Nigri, Usti, and Nidulante) and different cryptospecies were found. Among Scedosporium, three species were observed (Scedosporium apiospermum, Scedosporium aurantiacum and Scedosporium boydii). All Exophiala isolates were identified as Exophiala dermatitidis. Rare filamentous fungi were also found. All cases of ABPA were associated to the presence of A. fumigatus. Mixed colonization with other mould or rare fungi was observed in half of them. To our knowledge, this is the first prospective study of mould species in CF using molecular methods in Latin America. This study shows that Aspergillus sp., E. dermatitidis and Scedosporium sp. have a high frequency in CF patients from Argentina, and by far, A. fumigatus was the most commonly cultured species. Continuous clinical surveillance is required to detect the emergence of new fungal pathogens and to detect resistant or difficult-to-treat species capable of chronic colonizing the airways and of hematogenous dissemination in case of lung transplantation.

4 July 2022 in New Zealand Veterinary Journal
Verified
Journal Article
Closed access
TDT Brito Devoto
T Brito Devoto
MTMa Toscanini
Ma Toscanini
KAK Hermida Alava
K Hermida Alava
AEAlejandro Etchecopaz
Alejandro Etchecopaz
SPSj Pola
Sj Pola
MCMl Cuestas
Ml Cuestas
To survey the diversity of fungal species that may be cultured from Antarctic penguins and pinnipeds, and to test the in vitro susceptibility to triazole drugs of any medically important Aspergillu...

30 August 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
VFVíctor Briceño Fernández
Víctor Briceño Fernández
KAKatherine Hermida Alava
Katherine Hermida Alava
EBEzequiel Bernabeu
Ezequiel Bernabeu
PFPedro Fuentes
Pedro Fuentes
TDTomas Brito Devoto
Tomas Brito Devoto
MMMarcela A. Moretton
Marcela A. Moretton

24 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SCShaul Cemal
Shaul Cemal
MLMaría Florencia Ladetto
María Florencia Ladetto
KAKatherine Hermida Alava
Katherine Hermida Alava
GKGila Kazimirsky
Gila Kazimirsky
MCMarcela Cucher
Marcela Cucher
Gerardo BykGerardo Byk
Gerardo Byk
Filamentous fungi, in particular the species Aspergillus, Scedosporium and Exophiala, frequently colonize the lungs of cystic fibrosis (CF) patients. Chronic colonization is linked to hypersensitivity reactions and persistent infections leading to a significant long-term decline in lung function. Azole antifungal therapy such as voriconazole (VRC) slows disease progression, in particular in patients with advanced CF; however, excessive mucus production in CF lungs poses a diffusional barrier to effective treatment. Here, biodegradable nanohydrogels (NHGs) recently developed as nanocarriers, were evaluated for formulating VRC as a platform for treating fungal infections in CF lungs. The NHGs entrapped up to about 30 μg/mg of VRC, and physicochemical properties were investigated by dynamic laser light scattering and nanoparticle tracking analysis. Diameters were 100–400 nm, and excellent colloidal stability was demonstrated in interstitial fluids indicating potential for pulmonary delivery. Nano-formulations exhibited high in vitro cytocompatibility in A549 and HEK293T cells and were tested for release of VRC under two different sink conditions. Notably, the antifungal activity of VRC-loaded nanohydrogels was at least two-fold greater than an aqueous suspension drug against different fungal species isolated from CF sputum, regardless of the presence of a CF artificial mucus layer. These findings support the development of potent VRC nano-formulations for treating fungal disorders in CF lungs.

1 January 2018 in Revista chilena de infectología
Verified
Journal Article
Open access
PDF file
MGManuel González-González
Manuel González-González
CCConsuelo Correa-Sierra
Consuelo Correa-Sierra
KHKatherine Hermida-Álava
Katherine Hermida-Álava
AMAna Machado-Díaz
Ana Machado-Díaz
LGL. Fernando Gómez-Andrade
L. Fernando Gómez-Andrade
VKVivian Kourí-Cardellá
Vivian Kourí-Cardellá
Palabras clave Ecuador; VIH; resistencia; anti-retroviral; mutaciones; subtipos

30 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SCShaul Cemal
Shaul Cemal
MLMaría Florencia Ladetto
María Florencia Ladetto
KAKatherine Hermida Alava
Katherine Hermida Alava
GKGila Kazimirsky
Gila Kazimirsky
MCMarcela Cucher
Marcela Cucher
Gerardo BykGerardo Byk
Gerardo Byk
Background/Objectives: Filamentous fungi, in particular the species Aspergillus, Scedosporium, and Exophiala, frequently colonize the lungs of cystic fibrosis (CF) patients. Chronic colonization is linked to hypersensitivity reactions and persistent infections leading to a significant long-term decline in lung function. Azole antifungal therapy such as voriconazole (VRC) slows disease progression, particularly in patients with advanced CF; however, excessive mucus production in CF lungs poses a diffusional barrier to effective treatment. Methods: Here, biodegradable nanohydrogels (NHGs) recently developed as nanocarriers were evaluated for formulating VRC as a platform for treating fungal infections in CF lungs. The NHGs entrapped up to about 30 μg/mg of VRC, and physicochemical properties were investigated via dynamic laser light scattering and nanoparticle tracking analysis. Diameters were 100–400 nm, and excellent colloidal stability was demonstrated in interstitial fluids, indicating potential for pulmonary delivery. Nano-formulations exhibited high in vitro cytocompatibility in A549 and HEK293T cells and were tested for the release of VRC under two different sink conditions. Results: Notably, the antifungal activity of VRC-loaded nanohydrogels was up to eight-fold greater than an aqueous suspension drug against different fungal species isolated from CF sputum, regardless of the presence of a CF artificial mucus layer. Conclusions: These findings support the development of potent VRC nano-formulations for treating fungal disorders in CF lungs.